Blockchain Registration Transaction Record
ABVC BioPharma Anticipates $7M Cash Licensing Income in 2025
ABVC BioPharma expects $7M in cash licensing income in 2025 from global agreements signed in 2023, focusing on ophthalmology, CNS, and oncology/hematology. Progress in botanical drug development and plans for utilizing land assets for growth are highlighted, positioning the company in expanding markets for MDD, ADHD, and botanical drugs.

This news matters as ABVC BioPharma's expected $7M cash licensing income and advancements in botanical drug development signify significant progress in the biopharmaceutical industry. The company's strategic positioning in expanding markets for MDD, ADHD, and botanical drugs highlights its commitment to innovative treatments and addressing unmet medical needs.
Blockchain | Details |
---|---|
Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
Transaction ID | 0x2840a09f14fc24524af260b29708d217c5f66326d689797335e442d7bbde3a8f |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | noteXjd7-8b84d896c55148454c76d37ec7184628 |